Eagle Global Advisors’s Harvard Bioscience HBIO Stock Holding History

Eagle Global Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13,124	Closed	-$335K	–	302
2017 Q2	$335K	Sell	13,124 -2,504	-16%	-$61.9K	0.01%	283
2017 Q1	$406K	Hold	15,628	–	–	0.01%	240
2016 Q4	$477K	Hold	15,628	–	–	0.01%	218
2016 Q3	$425K	Sell	15,628 -1,508	-9%	-$41.9K	0.01%	223
2016 Q2	$490K	Buy	17,136 +3,516	+26%	+$112K	0.01%	196
2016 Q1	$411K	Buy	13,620 +1,925	+16%	+$54.6K	0.01%	223
2015 Q4	$406K	Buy	11,695 +3,816	+48%	+$131K	0.01%	232
2015 Q3	$298K	Buy	7,879 +6,704	+571%	+$312K	0.01%	274
2015 Q2	$67K	Sell	1,175 -1,445	-55%	-$82.2K	﹤0.01%	376
2015 Q1	$152K	Buy	+2,620	New	+$141K	﹤0.01%	329

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

Eagle Global Advisors's HBIO Position: Q3 2017 in Review

Eagle Global Advisors sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 13,124 shares — an estimated $335K sold.

Eagle Global Advisors first reported a position in HBIO in Q1 2015 and held it in 10 quarters. The position peaked at $490K in Q2 2016. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

Eagle Global Advisors reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
Eagle Global Advisors sold 13,124 Harvard Bioscience shares in Q3 2017, an estimated $335K.
Eagle Global Advisors first reported a position in Harvard Bioscience in Q1 2015 and held it in 10 quarters.
Eagle Global Advisors's Harvard Bioscience position peaked at $490K in Q2 2016.
53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on Eagle Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.